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Abstract
 
Cancer vaccines aim at inducing (a) tumor-specific effector T cells able to reduce/eliminate the
tumor mass, and (b) long-lasting tumor-specific memory T cells able to control tumor relapse.
We have shown earlier, in 18 human histocompatibility leukocyte antigen (HLA)-A
 
*
 
0201
patients with metastatic melanoma, that vaccination with peptide-loaded CD34–dendritic cells
(DCs) leads to expansion of melanoma-specific interferon 
 
 
 
–producing CD8
 
  
 
T cells in the
blood. Here, we show in 9 out of 12 analyzed patients the expansion of cytolytic CD8
 
  
 
T cell
precursors specific for melanoma differentiation antigens. These precursors yield, upon single
restimulation with melanoma peptide–pulsed DCs, cytotoxic T lymphocytes (CTLs) able to
kill melanoma cells. Melanoma-specific CTLs can be grown in vitro and can be detected in
three assays: (a) melanoma tetramer binding, (b) killing of melanoma peptide–pulsed T2 cells,
and (c) killing of HLA-A
 
*
 
0201 melanoma cells. The cytolytic activity of expanded CTLs corre-
lates with the frequency of melanoma tetramer binding CD8
 
  
 
T cells. Thus, CD34-DC vaccines
can expand melanoma-specific CTL precursors that can kill melanoma antigen–expressing targets.
These results justify the design of larger follow-up studies to assess the immunological and clinical
response to peptide-pulsed CD34-DC vaccines.
Key words: tumor immunology • immunotherapy • cancer • vaccine • immunomonitoring
 
Introduction
 
Early studies in mice have demonstrated that tumor-specific
T cells can control tumor growth and metastasis (1–3). The
identification of T cell–defined tumor antigens in humans,
particularly in melanoma (4–8), facilitated the development
of tumor-specific immunotherapy (9, 10). Two independent
strategies are being pursued: (a) adoptive T cell therapy
where ex vivo–induced antigen-specific T cells are trans-
ferred into patients (11–13), and (b) vaccination to induce
therapeutic T cell immunity and tumor-specific immune
memory in vivo (14–17).
Considerable clinical responses have been observed after
adoptive transfer of melanoma antigen–specific CD8
 
  
 
T
cell clones and tumor-infiltrating T cell lines (18–20), dem-
onstrating the value of tumor-specific T cells in treatment
of cancer. Yet, passive transfer of T cells is not expected to
yield the long-lived tumor-specific immunity that might be
required to prevent tumor progression/relapse.
Cancer vaccines aim at inducing (a) tumor-specific effector
T cells able to reduce/eliminate the tumor mass, and (b)
long-lasting tumor-specific memory T cells able to control
tumor relapse. Owing to their capacity to induce and regulate
T cell immunity, DCs are increasingly used as adjuvants for
vaccination in cancer (21–23). The immunogenicity of
DCs charged with antigens ex vivo has now been demon-
strated in healthy volunteers (24) and in patients with cancer
(21, 25–27). Indeed, a number of pilot clinical trials have
used tumor antigen–loaded DCs as vaccines and demon-
strated safety as well as some clinical and immune responses
(28–35). We vaccinated 18 HLA-A
 
*
 
0201 patients with
metastatic melanoma with peptide-pulsed CD34-DCs. We
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have recently reported that vaccination with DCs led to
enhancement of melanoma-specific CD8
 
  
 
T cell immunity
as measured by IFN-
 
  
 
production (ELISPOT) upon in
vitro exposure to melanoma antigen–derived peptides (28,
36). Here, we further analyzed 12 patients to determine
whether vaccination with peptide-pulsed CD34-DCs per-
mits expansion of melanoma-specific CD8
 
  
 
T cells that can
yield functional CTLs able to kill melanoma antigen–
expressing cells. Melanoma-specific CD8
 
  
 
T cells were
measured after single restimulation with peptide-pulsed
DCs in three independent assays: (a) killing of melanoma
peptide–pulsed T2 cells, (b) killing of HLA-A
 
*
 
0201 allo-
genic melanoma cell lines, and (c) binding of melanoma
tetramers. Each of the assays indicates that CD34-DCs vac-
cines can enhance CTL precursors specific for melanoma
differentiation antigens.
 
Materials and Methods
 
Study Design, Patient Characteristics, and Eligibility Criteria
 
All of the details have been previously described (21, 28). In
brief, 18 HLA-A
 
*
 
0201 patients with metastatic melanoma were
injected with melanoma peptide–pulsed CD34-DCs. Inclusion
criteria were the following: biopsy-proven American Joint Com-
mittee on Cancer metastatic melanoma; age 
 
 
 
18 yr; Karnofsky
performance status 
 
 
 
80%; HLA-A
 
*
 
0201 phenotype; intradermal
skin test positive to recall antigen; normal blood CD4 and CD8
T cell numbers; and normal quantitative immunoglobulin levels.
Exclusion criteria included the following: prior chemotherapy or
biologicals 
 
 
 
4 wk before trial entry; untreated central nervous
system lesions; bulky hepatic metastatic lesions; pregnancy; or
concurrent corticosteroids/immunosuppressive therapy. All pa-
tients were presented with several treatment alternatives before
they gave a written informed consent. The study was approved
by the Food and Drug Administration, the National Cancer In-
stitute, and the Institutional Review Board. Patients received a
6-wk outpatient vaccination course with antigen-loaded CD34-
DCs given s.c. every 14 d for a total of four vaccinations. DCs
were administered in a dose-escalation design at the dose level
per cohort of 0.1, 0.25, 0.5, and 10
 
6 
 
DCs/kg/vaccination. 12 out
of 18 patients subsequently received additional vaccines as de-
scribed elsewhere (unpublished data).
The trial was initiated in 1999 and the majority of patients
completed the four vaccinations by mid 2000. Progressive disease
means the appearance of 
 
 
 
1 new lesions or 
 
 
 
20% increase in the
longest diameter of specified lesions, taking as reference the long-
est diameter recorded at the treatment onset according to RE-
CIST criteria (37). Nonprogressive disease means the absence of
disease progression as defined above. Patients underwent com-
puted tomographic (CT) scanning, magnetic resonance imaging,
or positron emission tomography scanning, and physical exami-
nation within 6 wk of the first vaccination and within 30 d after
the fourth vaccination (unless otherwise indicated). Details are
provided in Table I. All charts were reviewed by an independent
outside clinical monitor. Scans were reviewed by two indepen-
dent radiologists.
 
Preparation and Administration of the DC Vaccine
 
The procedure has been described in detail (21, 28). In brief,
DCs were generated by culture of CD34
 
  
 
hematopoietic progen-
itor cells with 50 ng/ml GM-CSF (Immunex), 100 ng/ml Flt3
liter (Immunex), and 10 ng/ml TNF (CellPro, Inc.). DC vac-
cine was pulsed with 2 
 
 
 
g/ml KLH (Intracell), 2.5 
 
 
 
g/ml
HLA-A
 
*
 
0201–restricted flu-matrix peptide (Flu-MP) GILGFV-
FTL
 
58-66
 
, and a mix of four HLA-A
 
*
 
0201–restricted peptides
derived from melanoma antigens (Melan A/MART-1
 
27–35
 
: AAG-
 
Table I.
 
Patient Characteristics
 
Patient number Previous therapy Disease sites on entry Status after four injections
4 Chemo/IL-2 IFN-
 
 
 
CT scan: subcarinal LN mass, pulmonary nodule CT scan: NPD
5 Chemo/IL-2 IFN-
 
 
 
CT and PET scan: spleen, liver, and lung nodules CT scan: NPD
6 Surgery/IL-2 CT scan and PE: skin nodules and LN PE: PD, new lesions
9 Surgery/RT cell vaccine PE: axillary LN mass PE: NPD
10 Surgery PE: femoral LN next to biopsy proven LN mass PE: NPD
12 Surgery/RT MRI and PE: skin nodule, CNS MRI and PE: NPD
13 Surgery/RT MRI and CT scan: axillary LN MRI and CT scan: PD in CNS
16 Chemo CT scan: retroperitoneal LN, liver CT scan: PD new lesions
17 Surgery CT and PET scan: lung nodules CT scan: NPD
18 Surgery CT/PET scan and PE: pericardial nodule and vaginal wall CT scan and PE: NPD
19 RT PET scan and PE: parotid nodule PE and CT scan: NPD
21 Surgery MRI and PE: three liver lesions MRI and PE: NPD
NPD, nonprogressive disease; PD, progressive disease; PE, physical exam; PET, positron emission tomography; MRI, magnetic resonance imaging;
CNS, central nervous system. Assessment of disease sites at baseline (pre) and after four DC vaccinations (post). Patient number 9: cell vaccine in 1995
while in stage III disease. CT scan at baseline negative. Patient number 10: CT scan of chest, abdomen, and pelvis negative at baseline. Patient number
12: received whole brain radiation therapy within 4 wk before first DC vaccination. Patient number 13: altered vaccination schedule due to
appearance of a central nervous system lesion after two vaccinations; the lesion was resected. Because of steroid therapy, the patient received two
additional vaccinations 3 mo later. Patient number 18: baseline scans performed 8 wk before first vaccination. Patient number 19: CT scan 2 mo after
fourth DC vaccination. 
Paczesny et al.
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IGILTV; gp100
 
g209–2M
 
: IMDQVPFSV; Tyrosinase
 
368–376
 
: YMDGT-
MSQV; MAGE-3
 
271–279
 
: FLWGPRALV; 2.5 
 
 
 
g/ml). Vaccine
was administered s.c. in three injection sites.
 
Assessment of CTL Precursors
 
Media and Reagents.
 
Complete culture medium (CM) con-
sisted of RPMI 1640, 1% 
 
l
 
-glutamine, 1% penicillin/streptomy-
cin, 1% sodium pyruvate, 1% nonessential amino acids, 25 mM
Hepes, and 10% heat-inactivated FCS (GIBCO BRL). For T cell
cultures, FCS was replaced by 10% human AB serum (Gemini
Bio-Products). 100 ng/ml GM-CSF (Leukine; Immunex), 25
ng/ml IL-4 (R&D Systems), 10 UI/ml IL-7 (R&D Systems), and
10 UI/ ml IL-2 (R&D Systems) were used.
 
Synthetic Peptides.
 
MelanA/MART-1
 
27–35 
 
(AAGIGILTV),
gp100
 
g209–2M
 
 (IMDQVPFSV), TYR
 
368–376 
 
(YMDGTMSQV),
Flu-MP
 
58–66 
 
(GILGFVFTL), CMV pp65
 
495–563 
 
(NLVPMVATV),
MAGE-3
 
271–279 
 
(FLWGPRALV), and PSA1
 
141–150 
 
(FLTPKK-
LQCV) were used.
 
Cell Lines.
 
K562, A375 melanoma cell line, MCF7 breast
cancer cell line, and T2 were from the American Type Culture
Collection. The Me275 and Me290 melanoma cell lines, estab-
lished at the Ludwig Cancer Institute in Lausanne, were provided
by J.-C. Cerottini and D. Rimoldi (Ludwig Institute for Cancer
Research, Lausanne, Switzerland). All cell lines were maintained
in CM.
 
Monocyte-derived DCs.
 
Monocyte-derived DCs were gener-
ated from G-CSF (Amgen)–mobilized PBMCs from either HLA-
A
 
*
 
0201 healthy volunteers (Institutional Review Board 097–053)
or from patients. Adherent monocytes were cultured for 6 d in
CM and GM-CSF plus IL-4. Maturation was induced by 30 h of
culture with LPS. At day 6, the DCs were loaded with 10 
 
 
 
g/ml
HLA-A
 
*
 
0201–restricted peptides overnight.
 
CD8
 
  
 
T Cell Purification.
 
PBMCs were depleted of NK cells
using CD56 and CD16 microbeads (Miltenyi Biotec) and CD8
 
 
 
T cells were positively selected using microbeads (
 
 
 
90% CD8
 
 
 
).
 
Recall Assay.
 
10
 
4 
 
peptide-loaded DCs were plated with 10
 
5 
 
T
cells in a final volume of 200 
 
 
 
l CM plus 10% AB serum, 10 UI/
ml IL-7 for 3 d, and 10 UI/ml IL-2 for 7 d.
 
Tetramer Analysis.
 
Streptavidin-PE–labeled tetramers were
purchased from Beckman Coulter. The peptides used for the tet-
ramers were NLVPMVATV (HLA-A
 
*
 
0201 CMV pp65
 
495–563
 
)
and the same peptides used for the vaccine: GILGFVFTL (HLA-
A
 
*
 
0201 Flu-MP
 
58–66
 
), ELAGIGILTV (HLA-A
 
*
 
0201 MelanA/
MART-1
 
27–35
 
), IMDQVPFSV (HLA-A
 
*
 
0201 gp100
 
g209–2M
 
),
YMDGTMSQV (HLA-A
 
*
 
0201 TYR
 
368–376
 
), and FLWGPR-
ALV (HLA-A
 
*
 
0201 MAGE-3
 
271–279
 
). After culture, the T cells
were divided into aliquots of 10
 
6 
 
cells/well in a 96-well plate. 5
 
 
 
l of each tetramer and 3 
 
 
 
l CD8 FITC or CD3 FITC were
added to pelleted cells. Pellets were resuspended and incubated at
room temperature for 30 min in the dark. After two washes with
PBS, the cells were resuspended in 1% paraformaldehyde in PBS
and analyzed by flow cytometry.
 
Cytotoxicity Assay and Class I MHC Blocking.
 
Cytotoxicity
was measured in a standard 4-h 
 
51
 
Cr release assay. In brief, T2
cells were pulsed overnight with 10 
 
 
 
g/ml of indicated peptides.
Targets (T2 cells and allogenic cell lines) were labeled with 
 
51
 
Cr
(NEN Life Science Products), washed, and cocultured (10
 
3
 
 cells)
at 37
 
 
 
C for 4 h with CTLs. Percentage of specific lysis was calcu-
lated as (cpm
 
experiment 
 
  
 
cpm
 
spontaneous release
 
)/(cpm
 
maximum release 
 
 
 
cpm
 
spontaneous release
 
). 30 
 
 
 
g/ml anti-HLA ABC mAb (clone W6/
32; DakoCytomation) or 30 
 
 
 
g/ml isotype control–purified
mouse IgG2a (Becton Dickinson) was added at the onset of the
cytotoxicity assay.
 
Statistics
 
As the form of the relationships between our measurements
and the immunologic effectiveness is unknown, we used non-
parametric tests based on u-scores, i.e., Spearman correlation and
Mann-Whitney test, as indicated. To score activity profiles mea-
sured by the overall response to several melanoma antigens, we
used a novel extension of u-statistics to multivariate ordinal data
(38). In short, one first determines the partial ordering among all
pairs of patients based on their response profiles. If one patient has
a higher response than the other for some antigens and a lower
response in none, the former and the latter patient have a
“higher” and “lower” profile, respectively. If one patient has a
higher response in some antigens, but a lower response in others,
the pair-wise order among their profiles is undetermined, because
the relative importance of the antigens is unknown. For each pa-
tient, the u-score is then computed as the number of patients
whose profiles are lower, minus the number of patients whose
profiles are higher. Pairs with undetermined order do not con-
tribute to the score. These scores can then be used with standard
nonparametric methods including linear rank procedures such as
Spearman correlation (39, 40).
 
Online Supplemental Material
 
Table S1 shows CTL activity against peptide-pulsed T2 cells
and HLA-A
 
*
 
0201 tumor cell lines. Table S2 shows the percent-
age of CD8
 
 
 
 T cells that bind tetramer in the recall assay, and
Table S3 shows tetramer profiles. Tables S1–S3 are available at
http://www.jem.org/cgi/content/full/jem.20032118/DC1.
 
Results
 
Expansion of Melanoma-specific CTL Precursors in the Recall
Assay.
 
We investigated whether vaccination of patients
with metastatic melanoma with peptide-pulsed CD34-DCs
leads to expansion of melanoma-specific CD8
 
  
 
T cells,
which can mature into cytotoxic effectors upon single in
vitro restimulation with melanoma peptide–pulsed DCs.
CD8
 
  
 
T cells, isolated from apheresis samples collected ei-
ther at baseline or 2–4 mo after four vaccinations, were de-
pleted of CD16
 
  
 
CD56
 
  
 
cells and restimulated with autol-
ogous peptide-pulsed DCs with 10 U/ml IL-7 and IL-2.
We found robust proliferation of CD8
 
  
 
T cells (2.5–11-
fold) in cultures with both viral peptide– or melanoma
peptide–pulsed DCs. There was no difference in T cell
expansion between pre- and post-DC vaccination sam-
ples (unpublished data) or between the patients. Cultured
CD8
 
  
 
T cells were assessed in three assays: (a) killing of
peptide-pulsed T2 cells, (b) killing of HLA-A
 
*
 
0201 mela-
noma cells, and (c) binding of melanoma tetramers.
 
Expanded CTLs Are Able to Kill Melanoma Peptide–pulsed
T2 Cells.
 
Maturation of CD8
 
  
 
T cells into CTLs was first
assessed in a standard 4-h 
 
51
 
Cr release assay using as targets
T2 cells pulsed with either the four melanoma peptides
used in the vaccine, i.e., MelanA/MART-1, gp100, tyro-
sinase, and MAGE-3, or with a control peptide. Fig. 1, a and
b, shows the CTL activity of cultured CD8
 
  
 
T cells iso-
lated from post-DC vaccination blood of two patients. Pa-
tient number 9 restimulated CD8  T cells killed melanoma
peptide–pulsed T2 cells with 40% lysis at the E/T ratio ofExpansion of Melanoma-specific CTLs via CD34-DC Vaccine 1506
50:1 (Fig. 1 a). In contrast, restimulated CD8  T cells from
patient number 13 were not able to kill melanoma pep-
tide–loaded T2 cells (Fig. 1 b). Killing was specific as no ly-
sis of PSA peptide–pulsed T2 cells could be detected. Con-
trol cultures, in which CD8  T cells were restimulated
with CMV peptide–pulsed DCs (Fig. 1 a, Pt#9) or Flu-MP
peptide–loaded DCs (Fig. 1 b, Pt#13), yielded highly effi-
cient specific CTLs with  80% lysis at the E/T ratio of
50:1. These results suggested that some of the vaccinated
patients do not display circulating melanoma-specific T
cells able to mature into melanoma-specific CTLs, whereas
they show functional virus-specific CD8  T cells.
Sufficient numbers of post-DC vaccination PBMCs were
available to assess the CTL function of CD8  T cells from
12 of the 18 vaccinated patients (Table S1, available at http:
//www.jem.org/cgi/content/full/jem.20032118/DC1).
The median specific lysis was 21% after subtraction of values
obtained with control PSA peptide–pulsed T2 cells (range:
0–55%; Fig. 1 c). In 10 of these patients (nos. 5, 6, 9, 10, 12,
13, 16, 17, 18, and 19) the killing of melanoma peptide–
pulsed T2 cells could be compared prevaccination and af-
ter the fourth vaccination. After vaccination, restimulated
CD8  T cells from seven patients (nos. 5, 9, 10, 12, 17, 18,
and 19) showed more than twofold higher killing of mela-
noma peptide–pulsed T2 cells than before vaccination. Kill-
ing of T2 cells pulsed with control PSA peptide was not in-
creased, consistent with specificity (Table S1).
Thus, vaccination with peptide-pulsed CD34-DCs leads
to expansion of circulating melanoma-specific CD8  T
cells that can mature into melanoma-specific CTLs able to
kill model target cells expressing melanoma antigen.
Expanded CTLs Are Able to Kill Melanoma Cells. Al-
though T2 cells facilitate determination of antigen specific-
ity, they do not yield conclusion as to whether a given cy-
totoxic cell can actually kill tumor cells. The cultured
CD8  T cells were analyzed for their capacity to kill the
HLA-A*0201 melanoma cell lines Me275 and Me290. The
use of allogenic melanoma cell lines expressing endogenous
antigens to measure the immune response to DC vaccina-
tion has an advantage over the autologous tumor, available
only in a few of our patients, as it allows comparing the T
cell functions of different patients and avoids the tumor-
dependent variability.
Fig. 2 shows the CTL activity of restimulated CD8  T
cells from patient number 12, which killed two melanoma
cell lines, Me290 and Me275 (25% specific lysis), even at a
relatively low E/T ratio of 25:1 (Fig. 2 a). No killing of
control targets, the HLA-A*0201 MCF7 breast cancer cell
line, and the NK-sensitive K562, was observed. Killing of
melanoma cells was restricted by the expression of HLA
class I, as the pretreatment of target cells with the HLA class
I–blocking mAb W6/32 resulted in  90% inhibition of
Me275 killing at different E/T ratios (Fig. 2 b, Pt#12). In
line with the results observed with melanoma peptide–
pulsed T2 cells, patient number 13’s CD8  T cells did not
kill melanoma cell lines (Table S1).
The capacity of cultured CD8  T cells from post-DC
vaccination blood to kill melanoma cell lines was then ana-
lyzed in 12 patients (Fig. 3 and Table S1). The median-spe-
cific lysis of Me275 cells was 12% (range: 0–39). The lysis
of control MCF7 and K562 cells was 8 (range: 0–17) and
9% (range: 0–46), respectively. Independent experiments
measuring CD8  T cells from the same patient yielded re-
producible results (Table S1). No induction of CTL activ-
ity against Me275 melanoma cells could be found when
Figure 1. CTL activity against melanoma peptide–pulsed T2 cells before
and after vaccination. Purified CD8  T cells after a single stimulation with
peptide-pulsed DCs are used as effectors in a standard 4-h 51Cr assay with
T2 cells pulsed with either a control PSA peptide, or with viral peptides
(Flu-MP, CMV), or with a mix of the four melanoma peptides (GP100,
MART-1/Melan A, tyrosinase, and MAGE-3) at indicated E/T ratios.
(a) CD8  T cells from patient number 9 (see Table I, after fourth DC
vaccine) are capable of specific lysis (ordinate) of T2 cells pulsed with viral
(CMV) or melanoma peptides at several E/T ratios (abscissa). (b) CD8  T
cells from patient number 13 (see Table I, after fourth DC vaccine) are
capable of specific lysis (ordinate) of T2 cells pulsed with Flu-MP peptide
at several E/T ratios (abscissa), but not of melanoma peptide–pulsed T2
cells. (c) Killing of melanoma peptide–pulsed T2 cells (a mix of four mel-
anoma peptides) by cultured CD8  T cells from all tested patients at base-
line (Pre) and after fourth DC vaccination (Post). Ordinate/specific lysis
at the E/T ratio of 30–25:1, after subtraction of values obtained with PSA
peptide–loaded T2 (see Table S1), patient number (see Table I). All experi-
ments are shown.Paczesny et al. 1507
CD8  T cells from three healthy HLA-A*0201 volunteers
were used (median 2%).
In 10 of these 12 patients, the killing of melanoma cells
could be compared prevaccination and after the fourth DC
vaccination. As shown in Fig. 3, there was a significant in-
crease in the lysis of Me275 melanoma cells post-DC vacci-
nation, but not of control K562 and MCF7 cells. CD8  T
cells from seven patients showed a more than twofold in-
crease in Me275 melanoma cell killing after DC vaccinations
(Fig. 3). The patient with the highest prevaccination CTL
activity also had IFN- –making T cells in the ELISPOT as-
say using pre-DC vaccination PBMCs (28). These results
suggest that peptide-pulsed CD34-DC vaccination can en-
hance melanoma-specific CTLs able to kill melanoma cells.
Expanded CTLs Bind Melanoma Tetramers. The in-
creased ability of cultured CD8  T cells to kill tumor tar-
gets could reflect an increased function of specific T cells
and/or an increased frequency. Therefore, we measured
the frequency of melanoma-specific CD8  T cells using
tetramers loaded with the four melanoma peptides used for
vaccination, i.e., gp100, MART-1/Melan A, tyrosinase,
and MAGE-3. The binding of Flu-MP tetramer was also
analyzed as the Flu-MP peptide was a component of the
DC vaccine. The frequency of melanoma-specific T cells
was determined as the fraction of CD8  T cells showing
high intensity staining (41).
Fig. 4 shows examples of tetramer staining in cultured
CD8  T cells, which efficiently killed Me275 melanoma
cells (Fig. 3, #17 and #21). CD8  T cells from patient num-
ber 17 (Fig. 4 a) displayed predominant specificity for one
antigen, i.e., gp100, with 16% of total tetramer-binding T
cells, even higher than for Flu-MP–specific T cells (Fig. 4
a, 13.5%). MART-1–specific CD8  T cells, and tyrosin-
ase- and MAGE-3–specific T cells, were barely detectable.
CD8  T cells from patient number 21 contained cells spe-
cific for three of the four melanoma peptides used for immu-
nization, i.e., gp100 (13.5%), MART-1 (1.6%), and MAGE-3
(2.2%; Fig. 4 b). CD8  T cells specific for gp100 could be
detected in this patient (patient no. 21) in the cultured pre-
vaccination T cells, albeit at a lower frequency (5 vs. 13.5%),
a finding consistent with the CTL data shown above (Fig. 3)
and the earlier ELISPOT data from this patient (28).
Figure 2. CTL activity against
allogenic tumor cell lines. Purified
CD8  T cells after single stimula-
tion are used as effectors in a stan-
dard 4-h 51Cr assay with control
(K562 and MCF-7) and HLA-
A*0201 melanoma (Me275 and
Me290) cell lines at the indicated
E/T ratios. (a) Purified CD8  T
cells from patient number 12 (see
Table I, after fourth DC vaccine)
are capable of specific lysis (ordi-
nate) of two melanoma cells lines,
but do not kill control targets at several E/T ratios (abscissa). (b) Killing of Me275 cells is restricted by MHC class I expression on targets cells. Me275
cells are used without pretreatment or are preincubated with either an isotype control or anti–HLA class I W6/32 mAb and used as targets. Specific lysis
(ordinate) at two E/T ratios (abscissa) representative of three independent experiments with T cells from three patients is shown.
Figure 3. CTL activity against
allogenic tumor cell lines before
and after vaccination. Killing of
Me275 melanoma cells, and of
control MCF7 breast cancer and
K562 cells, by cultured CD8  T
cells from all patients tested at
baseline (Pre) and after fourth
DC vaccine (Post). Ordinate,
nonsubtracted specific lysis at the
E/T ratio of 30–25:1; abscissa,
patient number (see Table I).
Average of all experiments for
each patient (see Table S1) is
shown. Prevaccination PBMCs
were analyzed only once due to
the limited availability of cells.
Wilcoxon paired test.Expansion of Melanoma-specific CTLs via CD34-DC Vaccine 1508
The proportion of melanoma tetramer–binding T cells
among CD8  T cell cultures was measured in 10 patients
before vaccination and after 4 vaccinations (Fig. 4 c and
Table S2). The majority of the patients demonstrated
considerable increase in the proportion of gp100-specific
CD8  T cells and three patients (nos. 5, 10, and 12)
showed an increase in MART-1/Melan A–specific CD8 
T cells. The proportion of CD8  T cells binding tyrosinase
and/or MAGE-3 tetramer was much lower than that of
gp100 and/or MART-1, the mechanism of which remains
to be determined. Nevertheless, in some patients, consid-
erable increase in tyrosinase- and/or MAGE-3–specific
CD8  T cells post-DC vaccinations could be observed
(Fig. 4 c and Table S2). Thus, tetramer binding analysis in-
dicates that vaccination with peptide-pulsed CD34-DCs
leads to the expansion of melanoma-specific CD8  T cells.
Killing of Melanoma Antigen–expressing Targets Correlates
with Expansion of Tetramer-binding CD8  T Cells. Lastly,
we determined whether the increased killing of cells ex-
pressing melanoma antigens (either T2 or melanoma cells) in
response to DC vaccination correlates with the increased
frequency of melanoma-specific CD8  T cells, using
u-scores for the profiles of the counts of CD8  T cells bind-
ing each of the melanoma tetramers, i.e., gp100, MART-1/
Melan A, tyrosinase, and MAGE-3 (Table S3). As shown in
Fig. 5 a, the killing of melanoma peptide–pulsed T2 targets
was strongly correlated (r   0.75, P   0.006) with the over-
all frequency of melanoma-specific CD8  T cells. In con-
trast, there was no correlation between the frequency of
melanoma-specific CD8  T cells and the killing of control
PSA peptide–pulsed T2 targets (r   0.12, P   0.73; Fig. 5
a). In line with the T2 assay, the killing of Me275 melanoma
cells was strongly correlated (r   0.85, P   0.0008) with the
overall frequency of melanoma-specific CD8  T cells (Fig. 5
b). The killing of control cell lines MCF7 or K562, did not
correlate with the frequency of melanoma-specific CD8  T
cells (P   0.1), which again indicates specificity.
Thus, vaccination with antigen-loaded CD34-DC vac-
cines expands melanoma-specific CD8  T cell precursors
that promptly yield melanoma-specific CTLs.
Discussion
To the best of our knowledge, this represents the first
study in which the quality of melanoma-specific CTLs elic-
ited by vaccination with antigen-pulsed CD34-DCs was
systematically measured in a cohort of 12 patients in three
independent assays. The results show that vaccination with
CD34-DCs can elicit CD8  T cell precursors specific for
melanoma differentiation antigens. These precursors can
expand and mature into specific CTLs in a recall assay, i.e.,
upon single restimulation with melanoma peptide–pulsed
DCs. These CTLs can be detected by three independent
measurements: (a) binding of melanoma tetramers, (b) kill-
ing of melanoma peptide–pulsed T2 cells, and (c) killing of
HLA-A*0201 melanoma cells.
Most clinical DC vaccination studies reported thus far
measured CD8  T cell responses using antigen-specific
IFN-  ELISPOT as a parameter of T cell function and
specificity (for review see references 25 and 26). Only a
few studies demonstrated the induction of tumor-specific
cytotoxic T cells using as targets either peptide-pulsed T2
cells (29, 35, 42) or tumor RNA–loaded DCs (43). Except
for two studies (44, 45), the induction of CTLs active
Figure 4. Flow cytometry
analysis of tetramer binding by
expanded CD8  T cells. Restim-
ulated CD8  T cells are labeled
with anti–CD8-FITC (abscissa)
and PE tetramers of a given
specificity (ordinate). The analy-
sis is performed on T cells gated
on CD8 expression and the high
affinity T cells are distinguished
based on the intensity of tetramer
fluorescence (square). (a) Patient
number 17 and (b) patient number
21. For details, see Table S2. (c)
Comparison of the percentage of
high intensity tetramer binding
CD8  T cells (ordinate, log scale)
at baseline and after fourth DC
vaccination. Wilcoxon paired test.Paczesny et al. 1509
against tumor cells could be analyzed only in a limited
number of patients (33, 46, 47). In one study (44), 2 out of
10 patients with breast/ovarian cancer vaccinated with
peptide-pulsed monocyte-derived DCs displayed killing of
HLA-A*0201 tumor cell lines. In a second study (45), four
out of nine patients with glioblastoma vaccinated with pep-
tide-pulsed monocyte-derived DCs demonstrated the in-
duction of effector cells capable to kill autologous tumors.
We found that vaccination with peptide-pulsed CD34-
DCs leads to expansion of melanoma-specific cytolytic
CD8  T cell precursors in several patients. Enhancement of
melanoma-specific CD8  T cell immunity was assessed by
measuring their CTL function against multiple targets ex-
pressing melanoma antigens in a standard 4-h 51Cr release
assay. The release of 51Cr from labeled melanoma cells was
significantly higher after culture with T cells isolated from
post-DC vaccination blood as compared with T cells iso-
lated at baseline. Yet, in some patients the expanded CD8 
T cells induced low 51Cr release from labeled melanoma
cells ( 10% of specific lysis, patients 9, 10, 18, and 19). Be-
cause loading Me275 melanoma cells with a mix of the
four melanoma peptides did not significantly increased the
killing (unpublished data), the recognition of endogenous
antigen was not a limiting factor. Determination of specific
lysis is particularly complex when analyzing the killing of
tumor cells. Two issues present themselves in the data in-
terpretation, i.e., the lysis of control tumor cell lines and
low 51Cr release. We interpret the observed lysis of K562
and MCF7 cells as the reflection of lytic activity of NK
cells and therefore, we have chosen to present all the data
without subtractions or thresholds. Indeed, the lysis of
MCF7 or K562 cells did not correlate with the frequency
of melanoma tetramer–specific T cells present in T cell cul-
tures. Furthermore, although the killing of Me275 cells is
restricted by HLA class I expression and can be nearly abol-
ished by pretreatment of targets with respective mAb, this
was not the case with MCF7 cells. To resolve low 51Cr re-
lease, we have exploited alternative measurements of CTL
function. Preliminary data suggest that T cells from patients
9, 10, 18, and 19 were indeed able to reduce the number of
viable Me275 cells in cocultures, suggesting that 10% of
specific lysis at 4 h might indicate the presence of specific
CTLs (unpublished data). Thus, T cells may use different
mechanisms to control tumor survival/growth and a 51Cr
release assay may not be sufficient for their evaluation.
One patient (no. 21) displayed, before vaccination,
gp100-specific CD8  T cells able to kill melanoma cells. As
the only previous therapy was surgery, this suggests the ex-
istence of naturally occurring melanoma-specific immunity
(6). This observation is consistent with earlier observations
that melanoma-infiltrated LNs resected from patients may
contain MART-1/Melan A tetramer-binding CD8  T cells
that display memory phenotype and can be expanded in
vitro (48). Furthermore, previously untreated melanoma
patients may display melanoma tetramer–binding T cells in
the blood, particularly those specific for MART-1/Melan
A (49, 50). Yet, in the majority of patients these T cells do
not seem functional (28, 36, 49, 50).
We could measure CD8  T cells specific for gp100 and
MART-1, however, the frequency of T cells specific for
the two other antigens presented on the vaccine, i.e., tyro-
sinase and MAGE-3, was considerably lower. Although
this observation requires further studies, possible explana-
tions may arise from (a) frequency of precursors, with
MART-1 being higher than other specificities, (b) peptide
used for immunization, with mutated gp100 having a high
affinity for MHC class I (51), and (c) experimental condi-
tions that do not allow sufficient in vitro expansion of T
cells with lower frequency. For example, we cannot ex-
clude that culturing CD8  T cells with IL-2 leads to selec-
tion of certain specificities, whereas using other cytokines,
for example IL-15 (52, 53), or culturing in the presence of
CD4 T cells, might permit detection of a larger repertoire
of CD8  T cells.
Measuring the quality of melanoma-specific CD8  T cell
immunity in vaccinated patients revealed two groups of pa-
tients, i.e., those who did mount melanoma-specific CTLs
able to kill the tumor and those who did not. Such inability
to mount CD8  T cell immunity seems to be restricted to
melanoma antigens because highly efficient CMV- or Flu-
MP–specific CTLs can be generated from these patients’
blood. Thus, lack of melanoma-specific CTL induction is
not a consequence of a global alteration of the immune sys-
tem. The lack of melanoma-specific T cells by all three
measurements was particularly apparent in three patients
(nos. 6, 13, and 16), all of which experienced early disease
Figure 5. CTL function cor-
relates with the frequency of
tetramer-binding CD8  T cells.
(a) The specific lysis, by CD8  T
cells restimulated with melanoma
peptide–pulsed DCs, of melanoma
peptide–pulsed T2 cells (ordi-
nate), but not of PSA peptide–
pulsed T2 cells, correlates with
the frequency of all high affinity/
intensity melanoma tetramers
binding CD8   T cells deter-
mined used u-scores (abscissa).
Nonparametric Spearman correlation. (b) The specific lysis of Me275 melanoma cells by CD8 T cells restimulated with melanoma peptide–pulsed DCs
(ordinate) correlates with the frequency of all high affinity/intensity melanoma tetramers binding CD8  T cells determined used u-scores (abscissa).
There was no correlation between tetramer scores and the killing of control MCF7 cells. Nonparametric Spearman correlation.Expansion of Melanoma-specific CTLs via CD34-DC Vaccine 1510
progression with appearance of new lesions. Studies in
larger patient cohorts are necessary to determine whether
disease progression is indeed linked with the absence of
melanoma-specific immunity in response to vaccination.
In conclusion, concurring with earlier clinical studies
(29, 35), our study demonstrates that vaccination with DCs
can induce functional CD8  T cell immunity in cancer pa-
tients. The present results justify the design of larger fol-
low-up studies to assess the immunological and clinical re-
sponse to peptide-pulsed CD34-DC vaccines.
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